Stock analysis searches answered, part 2 of 43

Krakacquisition corp class a ordinary shares bullish and bearish analyst opinions

This section ties “Krakacquisition corp class a ordinary shares bullish and bearish analyst opinions” to KRAKacquisition Corp (ticker KRAQ, KRAQU, KRAQW), SEC Central Index Key 2082119, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-30 by KRAKacquisition Corp (CIK 2082119) — source document:

We are a blank check company incorporated on July 28, 2025 as a Cayman Islands exempted company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a “Business Combination”). While we may pursue an initial Business Combination in any business or industry or sector, we intend to concentrate our efforts on companies in the digital asset ecosystem. Our mission is to accelerate the next phase of growth for the teams building the bridge between DeFi and TradFi. We expect to focus on companies developing the core infrastructure of the digital asset economy-payment networks, tokenization platforms, blockchain infrastructure, compliance solutions, and other essential services.

Financial trend for KRAKacquisition Corp from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$8.91 million (2026-03-31) to $2.85 million (2026-06-30), a change of +131.9%; total assets went from $347.95 million (2026-03-31) to $350.77 million (2026-06-30), a change of +0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2082119, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures KRAKacquisition Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on KRAKacquisition Corp (CIK 2082119) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for KRAKacquisition Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B4, S-1, S-1MEF) appear in its recent index, the newest dated 2026-01-29.

Current reports. Of the 3 8-K or 6-K reports in KRAKacquisition Corp’s recent EDGAR index, the 3 listed here run from 2026-02-02 to 2026-03-19, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2082119 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2025-09-16. Insider trades for KRAKacquisition Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pt kmi wire and cable tbk forecast and analysis

The legal-form ending in “Pt kmi wire and cable tbk” is the clue: “PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. A company of that kind reports in Indonesia, so the place to read its annual report and announcements is the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK — www.idx.co.id.

No SEC filer could be matched to “Pt kmi wire and cable tbk forecast and analysis” with a single, clear Central Index Key: the phrase “Pt kmi wire and cable tbk” appears in 14 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “kmi” (search terms considered: kmi, wire, cable, forecast, analysis).

A broader EDGAR full-text search for the shorter phrase “Pt kmi wire” finds 33 filing documents; among the top 33, the filers mentioning it most are DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (9); DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (7); COMPOSITE TECHNOLOGY CORP (CIK 0000317477) (6). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “kmi” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 14 most relevant full-text hits returned for “Pt kmi wire and cable tbk”, filings range from 2008-12-23 to 2019-08-29. The filers whose documents mention it most often are COMPOSITE TECHNOLOGY CORP (CIK 0000317477) (4 hits); OLD WESTBURY FUNDS INC (CIK 0000909994) (2 hits); DFA INVESTMENT TRUST CO (CIK 0000896162) (2 hits); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (2 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 8 entities whose registered name contains the word “kmi”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “kmi” 8, “wire” 56, “cable” 357, “forecast” 9, “analysis” 51. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “kmi” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Mueller water products mwa latest news october 2026

This section ties “Mueller water products mwa latest news october 2026” to Mueller Water Products, Inc. (ticker MWA), SEC Central Index Key 1350593, an EDGAR registrant classified as “Miscellaneous Fabricated Metal Products” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2025-11-19 by Mueller Water Products, Inc. (CIK 1350593) — source document:

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 26 Equity Compensation Plan Information 26 Sale of Unregistered Securities 26 Issuer Purchases of Equity Securities 26 Stock Price Performance Graph 27 Item 6. [RESERVED] 27 Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 28 Overview 28 Results of Operations 30 Liquidity and Capital Resources 32 Material Cash Requirements 34 Effect of Inflation 35 Seasonality 35 Critical Accounting Estimates 35 Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK 36 Item 8. BUSINESS Our Company Mueller Water Products, Inc. (“Mueller,” “we,” “our,” or the “Company”) is a leading manufacturer and marketer of products and solutions used in the transmission, distribution and measurement of water in North America.

Financial trend for Mueller Water Products, Inc. from annual reports, periods 2022-09-30 to 2025-09-30: revenue went from $1.25 billion (2022-09-30) to $1.43 billion (2025-09-30), a change of +14.6%; net income (loss) went from $76.60 million (2022-09-30) to $191.70 million (2025-09-30), a change of +150.3%; total assets went from $1.50 billion (2022-09-30) to $1.84 billion (2025-09-30), a change of +22.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1350593, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Mueller Water Products, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Mueller Water Products, Inc. (CIK 1350593) filed 188 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-22, and its overall latest filing is a 8-K dated 2026-10-22. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 188 8-K or 6-K reports in Mueller Water Products, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-18 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1350593 is on the EDGAR company page; the latest 10-K there is dated 2025-11-19 and the oldest filing in the recent index dates from 2015-01-30. Insider trades for Mueller Water Products, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Privia health mobile apps

This section ties “Privia health mobile apps” to Privia Health Group, Inc. (ticker PRVA), SEC Central Index Key 1759655, an EDGAR registrant classified as “Services-Health Services” and organised in DE, formerly known as PH Group Parent Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-10-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-27 by Privia Health Group, Inc. (CIK 1759655) — source document:

Privia Health Group, Inc. (“Privia Health”, “we”, “our”, or the “Company”) is a technology-driven, national physician-enablement company that collaborates with physician practices, health plans, and health systems to achieve the quadruple aim of better outcomes, lower costs, improved patient experience, and happier and more engaged providers. We seek to accomplish the quadruple aim by entering markets and organizing existing physicians and non-physician clinicians into a unique practice model that combines the advantages of a partnership in a large regional medical group (each, a “Medical Group”) with significant provider autonomy for the physicians (collectively, “Privia Physicians”) and non-physician clinicians (collectively “Privia Clinicians” and, together with the Privia Physicians, the “Privia Providers”) in our Medical Groups.

Financial trend for Privia Health Group, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.36 billion (2022-12-31) to $2.12 billion (2025-12-31), a change of +56.5%; net income (loss) went from -$8.59 million (2022-12-31) to $22.92 million (2025-12-31), a change of +367.0%; total assets went from $792.81 million (2022-12-31) to $1.37 billion (2025-12-31), a change of +72.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1759655, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 4 periods shown, dashes mark figures Privia Health Group, Inc. did not tag for that period.

The search also names a website or app. Product logins, apps and web pages are run by the company, not the SEC; the EDGAR record for Privia Health Group, Inc. (CIK 1759655) lists its business address as 950 N. GLEBE RD., SUITE 700, ARLINGTON, VA, which helps confirm you are on the right company’s site.

Current reports. Of the 66 8-K or 6-K reports in Privia Health Group, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-22 to 2026-08-18, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1759655 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2019-02-13. Insider trades for Privia Health Group, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Sinda silver mexico

What this search refers to. “Sinda silver mexico” names a silver-related business with a Mexico connection; Mexican mining concessions and companies are not SEC registrants unless they list in the U.S., and Mexican public issuers report to the BMV. Official source: www.bmv.com.mx.

No SEC filer could be matched to “Sinda silver mexico” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Sinda silver mexico”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “sinda” (search terms considered: sinda, silver, mexico).

The wording suggests a business based in Mexico. Companies there file with the Mexican Stock Exchange (BMV) and the CNBV rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “sinda” is therefore the Mexico regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 1 entities whose registered name contains the word “sinda”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “sinda” 1, “silver” 459, “mexico” 352. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “sinda”: SINDA LTD. (CIK 2096861); containing “silver”: 06 SILVER DEPUTY BELOVED LLC (CIK 1435216), 06 SILVER DEPUTY DAISY DUKES LLC (CIK 1429800), 07 MACHO UNO/VICTORIAN SILVER LLC (CIK 1449174); containing “mexico”: AAM MEXICO HOLDINGS LLC (CIK 2129688), ACCIONES Y VALORES DE MEXICO SA DE CV (CIK 1279368), ADESA MEXICO, LLC (CIK 1424056). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “sinda” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

(oshkosh corp. or osk or general dynamics corporation or gd or axon enterprise, inc. common stock or axon or kratos defense & security solutions, inc. common stock or ktos) and (latest news or contracts or earnings or guidance)

Also searched as: (oshkosh corp. or osk or general dynamics corporation or gd or axon enterprise, inc. common stock or axon or kratos defense & security solutions, inc. common stock or ktos) and (latest news or contracts or earnings guidance); (oshkosh corp. or osk) and (latest news or contracts or earnings guidance) or (general dynamics corporation or gd) and (latest news or contracts or earnings guidance) or (axon enterprise, inc. common stock or axon) and (latest news or contracts or earnings guidance) or (kratos defense & security solutions, inc. common stock or ktos) and (latest news or contracts or earnings guidance)

A Boolean defence-and-security search over Oshkosh, General Dynamics, Axon and Kratos, with tickers given as alternatives. Every name is matched to its own EDGAR record (checked Oct 25, 2026), since none of these companies reports on behalf of another.

GENERAL DYNAMICS CORP (GD; ship & boat building & repairing, incorporated in DE) filed the 8-K of 2026-10-08 covering 5.02 (departure/election of directors or officers), 9.01 (financial statements and exhibits); the 8-K of 2026-08-07 covering 5.02 (departure/election of directors or officers), 9.01 (financial statements and exhibits). Year to 2025-12-31: FY revenue tagged at $52.55 billion, profit or loss $4.21 billion (10-K, 2026-01-30).

OSHKOSH CORP (OSK; motor vehicles & passenger car bodies, incorporated in WI): its index shows the 8-K of 2026-07-28 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-05-08 covering 5.07 (submission of matters to a vote of security holders). Year to 2018-09-30: reported revenue $7.71 billion (10-K, 2018-11-20).

KRATOS DEFENSE & SECURITY SOLUTIONS, INC. (KTOS; guided missiles & space vehicles & parts, incorporated in DE): its index shows the 8-K of 2026-08-04 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-05-15 covering 5.07 (submission of matters to a vote of security holders), 9.01 (financial statements and exhibits). Year to 2017-12-31: reported revenue $751.90 million, bottom line -$42.70 million (10-K, 2018-02-28).

AXON ENTERPRISE, INC. (AXON; ordnance & accessories, (no vehicles/guided missiles), incorporated in DE) — EDGAR lists the 8-K of 2026-09-21 covering 1.01 (entry into a material definitive agreement), 2.03 (creation of a direct financial obligation), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-09-15 covering 1.01 (entry into a material definitive agreement), 2.03 (creation of a direct financial obligation), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits). Year to 2025-12-31: annual sales of $2.78 billion, net result $124.66 million (10-K, 2026-02-25).

Frequency of Item 1.01 (entry into a material definitive agreement — the item a significant partnership or contract would be filed under) in recent filings — GD 0, OSK 6 (latest 2026-03-16), KTOS 6 (latest 2026-03-02), AXON 13 (latest 2026-09-21).

Updated Oct 25, 2026 ET

Itron abb eaton smart grid resilience latest

Also searched as: itron abb eaton smart grid grid resilience latest

Sample EDGAR registrant names, term by term — containing “itron”: ITRON INC /WA/ (CIK 780571), ITRON NETWORKED SOLUTIONS, INC. (CIK 1180079); containing “abb”: ABB FINANCE (USA) INC. (CIK 1548132), ABB FINANCIAL GROUP, INC. (CIK 1464353), ABB FUND I, A SERIES OF PF AL, LP (CIK 1885722); containing “eaton”: C. P. EATON PARTNERS, LLC (CIK 915764), EATON LABORATORIES INC (CIK 1164980), EATON AEROQUIP LLC (CIK 1583770); containing “smart”: A-SMART MOVIE LLC (CIK 1307424), A. SMART MOVE LLC (CIK 1377641), A. SMART MOVIE LLC (CIK 1336890); containing “grid”: AVENTAIL GRID & INFRASTRUCTURE OPPORTUNITIES FUND, LP (CIK 2053874), AVENTAIL GRID & INFRASTRUCTURE OPPORTUNITIES OFFSHORE FUND, LTD. (CIK 2078338), BEILLION CAPITAL LLC PROJECT GRID (CIK 2155266). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

Itron (metering and grid-edge software, CIK 780571) and Eaton (electrical equipment, CIK 1551182) both file annual 10-K reports with the SEC, while ABB is a Swiss group that reports under Swiss rules and publishes its own annual report rather than a 10-K. For smart-grid resilience, compare the segment disclosures: Itron’s Device, Networked and Outcomes segments versus Eaton’s Electrical Americas and Electrical Global segments, and ABB’s Electrification business area. Each company sets its own guidance, so recent order or backlog news for one says nothing direct about the others.

Updated Oct 25, 2026 ET

(coherent corp. or cohr) and (lumentum holdings inc. or lite) and (applied optoelectronics, inc. or aaoi) and (poet technologies inc. or poet) and (latest news or contracts or earnings or guidance)

Also searched as: (coherent corp. or cohr or lumentum holdings inc. or lite or applied optoelectronics, inc. or aaoi or poet technologies inc. or poet) and (latest news or contracts or earnings or guidance); (coherent corp. or cohr) or (lumentum holdings inc. or lite) or (applied optoelectronics, inc. or aaoi) or (poet technologies inc. or poet) and (latest news or contracts or earnings or guidance)

An all-of-these Boolean query requiring Coherent, Lumentum, Applied Optoelectronics and POET Technologies together — four optical-component makers. Every name is matched to its own EDGAR record (checked Oct 25, 2026), since none of these companies reports on behalf of another.

APPLIED OPTOELECTRONICS, INC. (AAOI; semiconductors & related devices, incorporated in DE) — EDGAR lists the 8-K of 2026-09-01 covering 1.01 (entry into a material definitive agreement), 2.03 (creation of a direct financial obligation), 9.01 (financial statements and exhibits); the 8-K of 2026-08-24 covering 1.01 (entry into a material definitive agreement), 5.02 (departure/election of directors or officers), 9.01 (financial statements and exhibits). Year to 2024-12-31: annual sales of $249.37 million, net result -$186.73 million (10-K, 2026-02-26).

Lumentum Holdings Inc. (LITE; communications equipment, nec, incorporated in DE) — EDGAR lists the 8-K of 2026-06-01 covering 3.02 (unregistered sales of equity securities); the 8-K of 2026-05-05 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2017-07-01: annual sales of $1.00 billion, net result -$102.50 million (10-K, 2018-08-28).

COHERENT CORP. (COHR; optical instruments & lenses, incorporated in PA) — EDGAR lists the 8-K of 2026-05-06 covering 2.02 (results of operations and financial condition), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-04-28 covering 5.02 (departure/election of directors or officers). Year to 2017-06-30: annual sales of $972.05 million, net result $95.27 million (10-K, 2018-08-28).

POET TECHNOLOGIES INC. (POET; semiconductors & related devices, incorporated in Ontario, Canada) — recent current reports: the 6-K of 2026-10-19; the 6-K of 2026-09-04. Year to 2025-12-31: revenue of $1.07 million, net income (loss) -$62.96 million (20-F, 2026-03-31).

Frequency of Item 1.01 (entry into a material definitive agreement — the item a significant partnership or contract would be filed under) in recent filings — AAOI 82 (latest 2026-09-15), LITE 12 (latest 2025-12-22), COHR 13 (latest 2025-09-26), POET 0.

Updated Oct 25, 2026 ET

Knightscope press release october 2026 kscp

Also searched as: knightscope press release kscp october 2026; knightscope kscp press release october 2026

This section ties “Knightscope press release october 2026 kscp” to Knightscope, Inc. (ticker KSCP), SEC Central Index Key 1600983, an EDGAR registrant classified as “Communications Equipment, NEC” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-27 by Knightscope, Inc. (CIK 1600983) — source document:

Our mission is to make the United States of America the safest country in the world. We serve clients across commercial, government, healthcare, education, transportation, and residential markets. ​ We are a security technology company headquartered in Sunnyvale, California. We provide integrated, technology-enabled security solutions designed to improve safety outcomes for our clients across the United States. ​ Our strategy is centered on building and delivering outcomes-driven safety through the integration of three core components that encompass our Knightscope Autonomous Security Force: ​ 1. Hardware – ASRs, ECDs, and a variety of sensing technologies; ​ 2. Software – cloud-based platform for real-time security monitoring, data analysis and event management, diagnostics tools designed to keep ECDs operational and reliable, and tools that enable the management and monitoring of ASRs in the field; and ​ 3.

Financial trend for Knightscope, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $5.63 million (2022-12-31) to $11.34 million (2025-12-31), a change of +101.3%; net income (loss) went from -$25.64 million (2022-12-31) to -$33.81 million (2025-12-31), a change of -31.9%; total assets went from $22.08 million (2022-12-31) to $41.26 million (2025-12-31), a change of +86.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1600983, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Knightscope, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Knightscope, Inc. (CIK 1600983) filed 49 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-20, and its overall latest filing is a 8-K dated 2026-10-20. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 49 8-K or 6-K reports in Knightscope, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-04 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1600983 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2014-02-27. Insider trades for Knightscope, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

F5 big-ip ltm cve

Also searched as: cve f5 big-ip ltm

This section ties “F5 big-ip ltm cve” to F5, INC. (ticker FFIV), SEC Central Index Key 1048695, an EDGAR registrant classified as “Computer Communications Equipment” and organised in WA, formerly known as F5 NETWORKS, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-15, and this view starts from filings dated on or before 2026-08-05. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2025-11-25 by F5, INC. (CIK 1048695) (passage 2, continuing from the earlier excerpt) — source document:

In addition, we sell high-performance systems, or hardware, as well as a broad range of global services including maintenance, consulting, training and other technical support services. Our customers include large enterprise businesses, public sector institutions, governments, and service providers. We conduct our business globally and manage our business by geography. Our business is organized into three primary geographic regions: Americas; Europe, the Middle East, and Africa ("EMEA"); and the Asia Pacific region ("APAC"). F5 was incorporated in 1996 and is headquartered in Seattle, Washington. Our website is www.f5.com and through a link on the Investor Relations section of our website, we make available the following filings as soon as reasonably possible after they are electronically filed with or furnished to the Securities and Exchange Commission ("SEC"): our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.

Financial trend for F5, INC. from quarterly and annual reports (three-month periods), periods 2025-12-31 to 2026-06-30: revenue went from $822.47 million (2025-12-31) to $865.08 million (2026-06-30), a change of +5.2%; net income (loss) went from $180.05 million (2025-12-31) to $208.21 million (2026-06-30), a change of +15.6%; total assets went from $6.29 billion (2025-12-31) to $6.83 billion (2026-06-30), a change of +8.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1048695, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 3 periods shown, dashes mark figures F5, INC. did not tag for that period.

Current reports. Of the 61 8-K or 6-K reports in F5, INC.’s recent EDGAR index, the 4 listed here run from 2025-10-15 to 2026-03-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1048695 is on the EDGAR company page; the latest 10-K there is dated 2025-11-25 and the oldest filing in the recent index dates from 2020-02-04. One example from this record is the 4 filed 2026-09-02 (document). Insider trades for F5, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Acadia healthcare achc latest news october 2026

This section ties “Acadia healthcare achc latest news october 2026” to Acadia Healthcare Company, Inc. (ticker ACHC), SEC Central Index Key 1520697, an EDGAR registrant classified as “Services-Specialty Outpatient Facilities, NEC” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-10-08. Nothing here is a recommendation to trade the security.

Financial trend for Acadia Healthcare Company, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.61 billion (2022-12-31) to $3.31 billion (2025-12-31), a change of +26.9%; net income (loss) went from $273.14 million (2022-12-31) to -$1.10 billion (2025-12-31), a change of -503.7%; total assets went from $4.99 billion (2022-12-31) to $5.53 billion (2025-12-31), a change of +10.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1520697, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Acadia Healthcare Company, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Acadia Healthcare Company, Inc. (CIK 1520697) filed 156 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-09-25, and its overall latest filing is a SCHEDULE 13G dated 2026-10-08. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 156 8-K or 6-K reports in Acadia Healthcare Company, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-06 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1000 recent EDGAR filings, Acadia Healthcare Company, Inc. most often filed 4 (528), 8-K (156), SC 13G/A (60), 10-Q (38). A selection from 2026-07-28 to 2026-10-08:

The full record for CIK 1520697 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2014-01-09. Insider trades for Acadia Healthcare Company, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Alpex acquisition corp. bullish and bearish analyst opinions

This section ties “Alpex acquisition corp. bullish and bearish analyst opinions” to Alpex Acquisition Corp (ticker ALPX, ALPXR, ALPXU, ALPXW), SEC Central Index Key 2125551, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-08-25. Nothing here is a recommendation to trade the security.

Financial trend for Alpex Acquisition Corp from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$59,856 (2026-03-31) to -$123,388 (2026-06-30), a change of -106.1%; total assets was tagged only for 2026-06-30 at $115.91 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2125551, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Alpex Acquisition Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Alpex Acquisition Corp (CIK 2125551) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Alpex Acquisition Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 4 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-06-25.

Current reports. Of the 3 8-K or 6-K reports in Alpex Acquisition Corp’s recent EDGAR index, the 3 listed here run from 2026-06-29 to 2026-07-02, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 26 recent EDGAR filings, Alpex Acquisition Corp most often filed 3 (6), SCHEDULE 13G (5), 8-K (3), SCHEDULE 13G/A (2). A selection from 2026-08-13 to 2026-08-25:

The full record for CIK 2125551 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-04-10. Insider trades for Alpex Acquisition Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Arista eos cve

This section ties “Arista eos cve” to Arista Networks, Inc. (ticker ANET), SEC Central Index Key 1596532, an EDGAR registrant classified as “Computer Communications Equipment” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-22. Nothing here is a recommendation to trade the security.

Vulnerability records for Arista EOS. Security flaws are catalogued by the U.S. National Vulnerability Database (NVD), run by NIST, not by the SEC. A keyword query of the NVD on Oct 25, 2026 returned 89 CVE entries whose descriptions mention Arista EOS; 44 of them were published in 2026, the newest being CVE-2026-73462 on 2026-09-16. Severity scores below are the CVSS base scores NVD lists; vendor advisories give fixed versions.

Business description, quoted from the 10-K filed 2026-02-17 by Arista Networks, Inc. (CIK 1596532) — source document:

In a world where data is increasingly a precious commodity and competitive differentiator, Arista was founded to enable our customers to access all their centers of data in the quickest, most reliable, and secure manner. Over the last two decades, we have emerged as an industry leader, delivering data-driven, client-to-cloud networking-as-a-service. Our “Centers of Data” strategy is a fundamental pivot from legacy networking approaches that create incongruent silos to a unified, data-driven approach in which the network is a service that interconnects four primary domains: AI Centers, Data Centers, Campus Centers, and WAN Centers. Anchored by Arista’s state-oriented Extensible Operating System (EOS) and Network Data Lake (NetDL), our network-as-a-service platform delivers a seamless, consolidated networking experience regardless of data location.

Financial trend for Arista Networks, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $4.38 billion (2022-12-31) to $9.01 billion (2025-12-31), a change of +105.5%; net income (loss) went from $1.35 billion (2022-12-31) to $3.51 billion (2025-12-31), a change of +159.6%; total assets went from $6.78 billion (2022-12-31) to $19.45 billion (2025-12-31), a change of +187.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1596532, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Arista Networks, Inc. did not tag for that period.

Current reports. Of the 36 8-K or 6-K reports in Arista Networks, Inc.’s recent EDGAR index, the 4 listed here run from 2026-02-12 to 2026-08-04, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1596532 is on the EDGAR company page; the latest 10-K there is dated 2026-02-17 and the oldest filing in the recent index dates from 2022-03-15. Insider trades for Arista Networks, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Banco itaú chile bullish and bearish analyst opinions

This section ties “Banco itaú chile bullish and bearish analyst opinions” to BANCO ITAU CHILE (ticker none listed), SEC Central Index Key 1276671, an EDGAR registrant classified as “Commercial Banks, NEC” and organised in Chile, formerly known as CORPBANCA/FI. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 15F-12B dated 2023-11-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2023-04-27 by BANCO ITAU CHILE (CIK 1276671) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS ​ 145 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES ​ 176 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS ​ 184 ITEM 8. FINANCIAL INFORMATION ​ 189 ITEM 9. OFFER AND LISTING DETAILS ​ 190 ITEM 10. ADDITIONAL INFORMATION ​ 190 ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT FINANCIAL RISK ​ 214 ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES ​ 237 PART II ​ 238 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES ​ 238 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS ​ 238 ITEM 15. CONTROLS AND PROCEDURES ​ 238 ITEM 16. RESERVED ​ 239 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT ​ 239 ITEM 16B. ETHICS ​ 240 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES ​ 240 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES ​ 240 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS ​ 241 ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT ​ 241 ITEM 16G. CORPORATE GOVERNANCE ​ 242 ITEM 16H.

Financial trend for BANCO ITAU CHILE from annual reports, periods 2019-12-31 to 2022-12-31: net income (loss) went from 124,522,000,000 CLP (2019-12-31) to 443,360,000,000 CLP (2022-12-31), a change of +256.0%; total assets went from 33,610,056,000,000 CLP (2019-12-31) to 40,320,766,000,000 CLP (2022-12-31), a change of +20.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1276671, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures BANCO ITAU CHILE did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BANCO ITAU CHILE (CIK 1276671) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2023-04-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 502 8-K or 6-K reports in BANCO ITAU CHILE’s recent EDGAR index, the 4 listed here run from 2023-11-03 to 2023-11-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1276671 is on the EDGAR company page; the latest 20-F there is dated 2023-04-27 and the oldest filing in the recent index dates from 2003-12-18. Insider trades for BANCO ITAU CHILE appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bioceres crop solutions corp. bullish and bearish analyst opinions

This section ties “Bioceres crop solutions corp. bullish and bearish analyst opinions” to Bioceres Crop Solutions Corp. (ticker BIOX), SEC Central Index Key 1769484, an EDGAR registrant classified as “Agricultural Chemicals” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-09-21. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2025-11-10 by Bioceres Crop Solutions Corp. (CIK 1769484) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 71 A. Operating Results 71 B. Liquidity and Capital Resources 82 C. Research and Development, Patents and Licenses, etc. 86 D. Trend Information 86 E. Critical Accounting Estimates 86 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 86 A. Directors and Senior Management 86 B. Compensation 88 C. Board Practices 89 D. Employees 91 E. Share Ownership 92 F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation 92 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 93 A. Major Shareholders 93 B. Related Party Transactions 95 C. Interests of Experts and Counsel 98 ITEM 8. FINANCIAL INFORMATION 98 A. Consolidated Statements and Other Financial Information 98 B. Significant Changes 99 ITEM 9.

Financial trend for Bioceres Crop Solutions Corp. from annual reports, periods 2022-06-30 to 2025-06-30: revenue went from $334.84 million (2022-06-30) to $335.11 million (2025-06-30), a change of +0.1%; net income (loss) went from -$3.91 million (2022-06-30) to -$58.85 million (2025-06-30), a change of -1405.4%; total assets went from $518.22 million (2022-06-30) to $763.65 million (2025-06-30), a change of +47.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1769484, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Bioceres Crop Solutions Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Bioceres Crop Solutions Corp. (CIK 1769484) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2025-11-10. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 124 8-K or 6-K reports in Bioceres Crop Solutions Corp.’s recent EDGAR index, the 4 listed here run from 2026-06-01 to 2026-09-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1769484 is on the EDGAR company page; the latest 20-F there is dated 2025-11-10 and the oldest filing in the recent index dates from 2019-03-14. Insider trades for Bioceres Crop Solutions Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Dauch corporation dch latest news october 2026

This section ties “Dauch corporation dch latest news october 2026” to Dauch Corp (ticker DCH), SEC Central Index Key 1062231, an EDGAR registrant classified as “Motor Vehicle Parts & Accessories” and organised in DE, formerly known as AMERICAN AXLE & MANUFACTURING HOLDINGS INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-13 by Dauch Corp (CIK 1062231) — source document:

Effective January 26, 2026, American Axle & Manufacturing Holdings, Inc. changed its name to Dauch Corporation. General Development of Business The Company, a Delaware corporation, is a successor to American Axle & Manufacturing of Michigan, Inc., a Michigan corporation, pursuant to a migratory merger between these entities in 1999. In 2017, we acquired Metaldyne Performance Group, Inc. (MPG), with MPG becoming a wholly-owned subsidiary of the Company. On February 3, 2026, we completed our previously announced acquisition of Dowlais Group plc (Dowlais) whereby we acquired the entire issued share capital of Dowlais (the Business Combination). Pursuant to the Business Combination, Dowlais shareholders received for each Dowlais ordinary share: 0.0881 shares of new Company common stock and 43 pence per share in cash (approximately $0.59 per share as of the closing date), resulting in the issuance of approximately 117 million shares (and an increase in authorized shares from 150 million to 375 million shares) and a total purchase price of approximately $1.7 billion.

Financial trend for Dauch Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $5.80 billion (2022-12-31) to $5.84 billion (2025-12-31), a change of +0.6%; net income (loss) went from $64.30 million (2022-12-31) to -$19.70 million (2025-12-31), a change of -130.6%; total assets went from $5.47 billion (2022-12-31) to $6.67 billion (2025-12-31), a change of +22.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1062231, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Dauch Corp did not tag for that period.

For the latest news, the fastest official source is the filing feed: Dauch Corp (CIK 1062231) filed 184 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-13, and its overall latest filing is a 8-K dated 2026-10-13. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 184 8-K or 6-K reports in Dauch Corp’s recent EDGAR index, the 4 listed here run from 2026-05-08 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1062231 is on the EDGAR company page; the latest 10-K there is dated 2026-02-13 and the oldest filing in the recent index dates from 2012-05-09. Insider trades for Dauch Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Gyrodyne, llc forecast and analysis

This section ties “Gyrodyne, llc forecast and analysis” to Gyrodyne, LLC (ticker GYRO), SEC Central Index Key 1589061, an EDGAR registrant classified as “Opeators of Nonresidential Buildings” and organised in NY. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-27 by Gyrodyne, LLC (CIK 1589061) — source document:

Gyrodyne, LLC (including its subsidiaries, “Gyrodyne”, the “Company” or the “Registrant”) is a limited liability company formed under the laws of the State of New York whose primary business is the management of a portfolio of medical office and industrial properties and the pursuit of entitlements on such properties located in Suffolk (“Flowerfield”) and Westchester (“Cortlandt Manor”) Counties, New York. Substantially all of our developed properties are subject to leases in which the tenant reimburses the Company for a portion, all of or substantially all of the costs and/or cost increases for utilities, insurance, repairs, maintenance and real estate taxes. Certain leases provide that the Company is responsible for certain operating expenses.

Financial trend for Gyrodyne, LLC from annual reports, periods 2014-12-31 to 2025-12-31: revenue was tagged only for 2014-12-31 at $2.80 million; net income (loss) was tagged only for 2014-12-31 at -$3.11 million; total assets went from $43.88 million (2014-12-31) to $58.69 million (2025-12-31), a change of +33.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1589061, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Gyrodyne, LLC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Gyrodyne, LLC (CIK 1589061) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 50 8-K or 6-K reports in Gyrodyne, LLC’s recent EDGAR index, the 4 listed here run from 2025-11-07 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1589061 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2013-10-21. Insider trades for Gyrodyne, LLC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Hemab therapeutics ceo october 2026

This section ties “Hemab therapeutics ceo october 2026” to Hemab Therapeutics Holdings, Inc. (ticker COAG), SEC Central Index Key 2114044, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-25, and this view starts from filings dated on or before 2026-05-11. Nothing here is a recommendation to trade the security.

Other filings. Across its 50 recent EDGAR filings, Hemab Therapeutics Holdings, Inc. most often filed 3 (12), 4 (10), SCHEDULE 13G (8), 8-K (5). A selection from 2026-05-11 to 2026-05-21:

The full record for CIK 2114044 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-02-27. One example from this record is the 8-K filed 2026-08-11 (document). Insider trades for Hemab Therapeutics Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Howard hughes holdings hhh sec filing october 2026

This section ties “Howard hughes holdings hhh sec filing october 2026” to Howard Hughes Holdings Inc. (ticker HHH), SEC Central Index Key 1981792, an EDGAR registrant classified as “Real Estate Investment Trusts” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-19 by Howard Hughes Holdings Inc. (CIK 1981792) — source document:

Howard Hughes Holdings Inc. (HHH or the Company) is a holding company that owns a real estate development subsidiary, The Howard Hughes Corporation (HHC). Through HHC, the Company operates a large‑scale, mixed‑use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income‑producing properties. Our award-winning assets include one of the nation's largest portfolios of MPCs, spanning approximately 101,000 gross acres across five states. We create some of the most sought-after communities in the country by curating an environment tailored to meet the needs of our residents and tenants. This unique business model allows us to seek attractive risk-adjusted returns while maintaining a sharp focus on sustainability to ensure our communities are equipped with the resources to last several decades.

Financial trend for Howard Hughes Holdings Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.49 billion (2022-12-31) to $1.47 billion (2025-12-31), a change of -1.0%; net income (loss) went from $184.53 million (2022-12-31) to $123.90 million (2025-12-31), a change of -32.9%; total assets went from $9.60 billion (2022-12-31) to $10.64 billion (2025-12-31), a change of +10.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1981792, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Howard Hughes Holdings Inc. did not tag for that period.

Howard Hughes Holdings Inc. has 293 filings in its recent EDGAR index, including 3 annual reports and 9 quarterly reports; its newest filing is a 8-K from 2026-10-23.

Current reports. Of the 44 8-K or 6-K reports in Howard Hughes Holdings Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-17 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1981792 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-29 and the oldest filing in the recent index dates from 2023-08-11. Insider trades for Howard Hughes Holdings Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Hoyne bancorp, inc. common stock bullish and bearish analyst opinions

This section ties “Hoyne bancorp, inc. common stock bullish and bearish analyst opinions” to Hoyne Bancorp, Inc. (ticker HYNE), SEC Central Index Key 2073153, an EDGAR registrant classified as “Savings Institutions, Not Federally Chartered” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a PRE 14A dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-26 by Hoyne Bancorp, Inc. (CIK 2073153) — source document:

Hoyne Bancorp, Inc. (“HYNE”, or the “Company”, “we” or “our”) is a Delaware corporation which was incorporated in June 2025 and completed its conversion to a stock form of ownership on December 3, 2025. Upon completion of the offering, Hoyne Bancorp, Inc. became a savings and loan holding company and Hoyne Savings, MHC and Hoyne Financial Corporation ceased to exist. As a savings and loan holding company, Hoyne Bancorp, Inc. is regulated by the Board of Governors of the Federal Reserve System (“Federal Reserve Board”). Hoyne Bancorp, Inc.’s primary business activity is owning all of the outstanding shares of capital stock of Hoyne Savings Bank. Hoyne Bancorp, Inc.’s executive offices are located at 810 S. Oak Park Avenue, Oak Park, Illinois 60304.

Financial trend for Hoyne Bancorp, Inc. from annual reports, periods 2024-12-31 to 2025-12-31: revenue went from $16.80 million (2024-12-31) to $20.37 million (2025-12-31), a change of +21.2%; net income (loss) went from -$1.96 million (2024-12-31) to $232,690 (2025-12-31), a change of +111.9%; total assets went from $449.51 million (2024-12-31) to $489.38 million (2025-12-31), a change of +8.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2073153, tags Assets, InterestAndDividendIncomeOperating, NetIncomeLoss; 2 periods shown, dashes mark figures Hoyne Bancorp, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Hoyne Bancorp, Inc. (CIK 2073153) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 6 8-K or 6-K reports in Hoyne Bancorp, Inc.’s recent EDGAR index, the 4 listed here run from 2025-11-28 to 2026-06-24, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2073153 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2025-06-17. Insider trades for Hoyne Bancorp, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Immutep limited bullish and bearish analyst opinions

This section ties “Immutep limited bullish and bearish analyst opinions” to IMMUTEP Ltd (ticker IMMP, PRRUF), SEC Central Index Key 1506184, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Australia, formerly known as Prima BioMed Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 20-F dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-10-23 by IMMUTEP Ltd (CIK 1506184) — source document:

Operating and Financial Review and Prospects 44 A. Operating Results 45 B. Liquidity and Capital Resources 48 C. Research and Development, Patents and Licenses 51 D. Trend Information 51 E. Critical Accounting Estimates 51 Item 6. Directors, Senior Management and Employees 52 A. Directors and Senior Management 52 B. Compensation 53 C. Board Practices 60 D. Employees 63 E. Share Ownership 63 F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation 64 Item 7. Major Shareholders and Related Party Transactions 64 A. Major Shareholders 64 B. Related Party Transactions 65 C. Interests of Experts and Counsel 65 Item 8. Financial Information 65 A. Consolidated Statements and Other Financial Information 65 B. Significant Changes 65 Item 9.

Financial trend for IMMUTEP Ltd from annual reports, periods 2022-06-30 to 2025-06-30: revenue went from 6,758,073 AUD (2022-06-30) to 10,331,373 AUD (2025-06-30), a change of +52.9%; net income (loss) went from -32,210,826 AUD (2022-06-30) to -61,434,165 AUD (2025-06-30), a change of -90.7%; total assets went from 102,169,550 AUD (2022-06-30) to 156,983,434 AUD (2025-06-30), a change of +53.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1506184, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures IMMUTEP Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on IMMUTEP Ltd (CIK 1506184) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-10-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 657 8-K or 6-K reports in IMMUTEP Ltd’s recent EDGAR index, the 4 listed here run from 2026-09-02 to 2026-10-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1506184 is on the EDGAR company page; the latest 20-F there is dated 2026-10-23 and the oldest filing in the recent index dates from 2012-02-13. Insider trades for IMMUTEP Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ithax acquisition corp iii analyst opinions and stock outlook

This section ties “Ithax acquisition corp iii analyst opinions and stock outlook” to ITHAX Acquisition Corp III (ticker ITHA, ITHAU, ITHAW), SEC Central Index Key 2080985, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-13, and this view starts from filings dated on or before 2025-12-18. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-24 by ITHAX Acquisition Corp III (CIK 2080985) (passage 2, continuing from the earlier excerpt) — source document:

Our Investment Thesis and Business Strategy The advent of digital assets and smart contracts as well as AI have already started to disrupt asset-management, hospitality, travel, entertainment, gaming and leisure and related services sectors. We intend to focus our initial business combination and value creation strategy on identifying a private company in the target sectors with a sound business and operating model and prospects, at a valuation that is attractive as compared to publicly-traded companies in the same target sector. Many of these companies have remained private for longer than prior market cycles. We believe that businesses in the target sectors can reap substantial benefits by being publicly listed and/or well capitalized as they can subsequently take advantage of market conditions in order to expand their businesses through organic growth, further acquisitions and/or sector consolidation.

Other filings. Across its 24 recent EDGAR filings, ITHAX Acquisition Corp III most often filed SCHEDULE 13G (4), 10-Q (3), 8-K (3), 3 (3). A selection from 2025-12-15 to 2026-01-27:

The full record for CIK 2080985 is on the EDGAR company page; the latest 10-K there is dated 2026-03-24 and the oldest filing in the recent index dates from 2025-08-21. One example from this record is the SCHEDULE 13G filed 2026-02-17 (document). Insider trades for ITHAX Acquisition Corp III appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ivvd reddit

This section ties “Ivvd reddit” to Invivyd, Inc. (ticker IVVD), SEC Central Index Key 1832038, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE, formerly known as Adagio Therapeutics, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-29. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-05 by Invivyd, Inc. (CIK 1832038) — source document:

Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody (“mAb”) therapies for the prevention and treatment of serious viral infectious diseases. We are devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19. PEMGARDA® (pemivibart) is our first mAb to receive regulatory authorization and was designed to exert continuous pharmaceutical activity in the face of viral evolution. Globally, COVID-19 has caused millions of deaths and lasting health problems in many survivors and remains a significant global health concern, particularly for immunocompromised individuals. COVID-19 persists and continues to impact patients, notably those who are immunocompromised, and combating this disease will require for years to come a variety of prevention and treatment options with demonstrated efficacy and safety.

Financial trend for Invivyd, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2023-12-31) to $53.43 million (2025-12-31); net income (loss) went from -$241.32 million (2022-12-31) to -$52.49 million (2025-12-31), a change of +78.2%; total assets went from $383.17 million (2022-12-31) to $276.88 million (2025-12-31), a change of -27.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1832038, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Invivyd, Inc. did not tag for that period.

Reddit threads about Invivyd, Inc., CIK 1832038, are user opinions, not disclosures. Claims made there can be checked against the filer record: 448 filings sit in its recent EDGAR index, the newest a 8-K dated 2026-09-29, and 122 insider Form 4 reports are among them. The SEC’s Investor.gov site warns that social-media hype around small listed companies is a common feature of pump-and-dump schemes.

Current reports. Of the 100 8-K or 6-K reports in Invivyd, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-24 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1832038 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2020-11-12. Insider trades for Invivyd, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Jena acquisition corporation ii forecast and analysis

This section ties “Jena acquisition corporation ii forecast and analysis” to JENA ACQUISITION Corp II (ticker JENA, JENA-RI, JENA-UN), SEC Central Index Key 2060337, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands, formerly known as JENA ACQUISITION CORPORARTION II. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-30 by JENA ACQUISITION Corp II (CIK 2060337) — source document:

We are a blank check company incorporated on February 24, 2025 as a Cayman Islands exempted company and formed for the purpose of effecting a Business Combination with one or more businesses or entities. We may pursue an initial Business Combination in any business or industry. To date, our efforts have been limited to (i) organizational activities, (ii) activities related to our Initial Public Offering, and (iii) searching for and consummating a Business Combination. As of the date of this Report, we have not selected any specific Business Combination target. We have generated no operating revenues to date, and we do not expect that we will generate operating revenues until we consummate our initial Business Combination.

Financial trend for JENA ACQUISITION Corp II from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $2.29 million (2025-09-30) to $1.88 million (2026-06-30), a change of -17.7%; total assets went from $234.53 million (2025-09-30) to $239.89 million (2026-06-30), a change of +2.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2060337, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures JENA ACQUISITION Corp II did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on JENA ACQUISITION Corp II (CIK 2060337) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for JENA ACQUISITION Corp II — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2025-05-29.

Current reports. Of the 4 8-K or 6-K reports in JENA ACQUISITION Corp II’s recent EDGAR index, the 4 listed here run from 2025-05-30 to 2026-04-03, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2060337 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2025-04-07. Insider trades for JENA ACQUISITION Corp II appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Liberty global lbtyk latest news october 2026

This section ties “Liberty global lbtyk latest news october 2026” to Liberty Global Ltd. (ticker LBTYA, LBTYB, LBTYK), SEC Central Index Key 1570585, an EDGAR registrant classified as “Cable & Other Pay Television Services” and organised in an unstated jurisdiction, formerly known as Liberty Global plc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-10-19. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-18 by Liberty Global Ltd. (CIK 1570585) — source document:

Who We Are We are Liberty Global Ltd. ( Liberty Global ), a dynamic team of operators and investors generating and delivering long-term shareholder value through the strategic management of three complementary platforms: Liberty Telecom, Liberty Growth and Liberty Services. Liberty Telecom is a world leader in converged broadband, video and mobile communications that has built fixed-mobile convergence ( FMC ) national champions through some of Europe’s best-known consumer brands. These brands deliver market-leading connectivity and entertainment products through next-generation networks, providing approximately 80 million fixed and mobile connections at December 31, 2025. We are pursuing strategies in each market to drive commercial momentum, finance and monetize network infrastructure and pursue accretive transactions that deliver value to our shareholders.

Financial trend for Liberty Global Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $1.47 billion (2022-12-31) to -$7.14 billion (2025-12-31), a change of -584.5%; total assets went from $42.90 billion (2022-12-31) to $22.60 billion (2025-12-31), a change of -47.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1570585, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Liberty Global Ltd. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Liberty Global Ltd. (CIK 1570585) filed 316 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-14, and its overall latest filing is a SCHEDULE 13G/A dated 2026-10-19. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 316 8-K or 6-K reports in Liberty Global Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-10-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1570585 is on the EDGAR company page; the latest 10-K/A there is dated 2026-03-26 and the oldest filing in the recent index dates from 2019-10-03. Insider trades for Liberty Global Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lockheed martin nextera energy ibm government partnership collaboration latest

A government-collaboration query spanning a defence contractor, a utility holding company and an IT services firm. What follows is each company’s own disclosure trail as EDGAR showed it on Oct 25, 2026.

LOCKHEED MARTIN CORP (LMT; guided missiles & space vehicles & parts, incorporated in MD) — recent current reports: the 8-K of 2026-10-22 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-08-28 covering 1.01 (entry into a material definitive agreement), 9.01 (financial statements and exhibits). Year to 2025-12-31: revenue of $75.05 billion, net income (loss) $5.02 billion (10-K, 2026-01-29).

NEXTERA ENERGY INC (NEE; electric services, incorporated in FL) — recent current reports: the 8-K of 2026-10-21 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-10-06 covering 8.01 (other events), 9.01 (financial statements and exhibits). Year to 2012-12-31: revenue of $14.26 billion, net income (loss) $1.91 billion (10-K, 2013-02-28).

INTERNATIONAL BUSINESS MACHINES CORP (IBM; computer & office equipment, incorporated in NY) — EDGAR lists the 8-K of 2026-10-21 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-10-01 covering 5.02 (departure/election of directors or officers), 5.03 (amendments to articles of incorporation or bylaws), 9.01 (financial statements and exhibits). Year to 2025-12-31: annual sales of $67.53 billion, net result $10.59 billion (10-K, 2026-02-24).

Item 1.01 — entry into a material definitive agreement — the item a significant partnership or contract would be filed under — appears this many times per company: LMT 12 (latest 2026-08-28), NEE 2 (latest 2026-05-18), IBM 8 (latest 2026-06-23).

Updated Oct 25, 2026 ET

Magnolia oil gas mgy latest news october 2026

This section ties “Magnolia oil gas mgy latest news october 2026” to Magnolia Oil & Gas Corp (ticker MGY), SEC Central Index Key 1698990, an EDGAR registrant classified as “Crude Petroleum & Natural Gas” and organised in DE, formerly known as TPG Pace Energy Holdings Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-01. Nothing here is a recommendation to trade the security.

Financial trend for Magnolia Oil & Gas Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.69 billion (2022-12-31) to $1.31 billion (2025-12-31), a change of -22.6%; net income (loss) went from $893.84 million (2022-12-31) to $325.25 million (2025-12-31), a change of -63.6%; total assets went from $2.57 billion (2022-12-31) to $2.90 billion (2025-12-31), a change of +12.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1698990, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Magnolia Oil & Gas Corp did not tag for that period.

For the latest news, the fastest official source is the filing feed: Magnolia Oil & Gas Corp (CIK 1698990) filed 89 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-01, and its overall latest filing is a 8-K dated 2026-10-01. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 89 8-K or 6-K reports in Magnolia Oil & Gas Corp’s recent EDGAR index, the 4 listed here run from 2026-08-05 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1698990 is on the EDGAR company page; the latest 10-K there is dated 2026-02-12 and the oldest filing in the recent index dates from 2017-02-28. Insider trades for Magnolia Oil & Gas Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Marwynn holdings, inc. common stock bullish and bearish analyst opinions

This section ties “Marwynn holdings, inc. common stock bullish and bearish analyst opinions” to Marwynn Holdings, Inc. (ticker MWYN), SEC Central Index Key 2030522, an EDGAR registrant classified as “Wholesale-Groceries, General Line” and organised in NV. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-07-30 by Marwynn Holdings, Inc. (CIK 2030522) — source document:

Marwynn Holdings, Inc., or “Marwynn,” was incorporated on February 27, 2024 in Nevada, as a holding company. We currently operate, or are developing operations, in three principal business areas: (i) electronic waste recycling (“E-waste Business”) through EcoLoopX Corporation (“EcoLoopX”); (ii) advanced artificial intelligence application development and related infrastructure solutions (“AI & Infrastructure Services”) through NexaCore Technologies, Inc. (“NexaCore”); and (iii) food and non-alcoholic beverage supply chain and brand management services through FuAn Enterprise, Inc. (“FuAn”). E-Waste Business As part of our business diversification strategy, we incorporated EcoLoopX on November 25, 2025. Its current strategy is to develop direct e-waste recycling operations and the capability to produce “black mass,” an intermediate material derived from processed lithium-ion batteries that may contain recoverable metals such as lithium, nickel, cobalt and copper.

Financial trend for Marwynn Holdings, Inc. from annual reports, periods 2024-04-30 to 2026-04-30: revenue went from $11.92 million (2024-04-30) to $4.24 million (2026-04-30), a change of -64.4%; net income (loss) went from $998,075 (2024-04-30) to -$3.92 million (2026-04-30), a change of -492.8%; total assets went from $12.56 million (2024-04-30) to $3.01 million (2026-04-30), a change of -76.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2030522, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Marwynn Holdings, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Marwynn Holdings, Inc. (CIK 2030522) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-07-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 17 8-K or 6-K reports in Marwynn Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-15 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2030522 is on the EDGAR company page; the latest 10-K/A there is dated 2026-09-22 and the oldest filing in the recent index dates from 2024-08-12. Insider trades for Marwynn Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pantages capital acquisition corp bullish and bearish analyst opinions

This section ties “Pantages capital acquisition corp bullish and bearish analyst opinions” to PANTAGES CAPITAL ACQUISITION Corp (ticker PGAC, PGACR, PGACU), SEC Central Index Key 2030829, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands, formerly known as PANTAGES CAPITAL ACQUSITION Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-10-06. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-09 by PANTAGES CAPITAL ACQUISITION Corp (CIK 2030829) — source document:

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination involving the Company, with one or more businesses or entities, which we refer to throughout this report as our “initial business combination”. We have neither engaged in any operations nor generated any revenue to date. Based on our business activities, we are a “shell company” as defined under the Securities Exchange Act of 1934 (the “Exchange Act”) because we have no operations and nominal assets consisting almost entirely of cash. On December 6, 2024, the Company consummated its initial public offering (the “IPO”) of 8,625,000 units (“Units”), including 1,125,000 additional Units granted to the underwriters to cover over-allotments, if any (the “over-allotment option”).

Financial trend for PANTAGES CAPITAL ACQUISITION Corp from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at $2.55 million; total assets went from $87.17 million (2024-12-31) to $90.36 million (2025-12-31), a change of +3.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2030829, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures PANTAGES CAPITAL ACQUISITION Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PANTAGES CAPITAL ACQUISITION Corp (CIK 2030829) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-09. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for PANTAGES CAPITAL ACQUISITION Corp — registration statements, prospectuses and merger proxies — are filed on EDGAR; 8 such filings (424B4, 425, S-1, S-1/A) appear in its recent index, the newest dated 2026-04-15.

Current reports. Of the 14 8-K or 6-K reports in PANTAGES CAPITAL ACQUISITION Corp’s recent EDGAR index, the 4 listed here run from 2026-06-10 to 2026-09-04, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2030829 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-29 and the oldest filing in the recent index dates from 2024-07-24. Insider trades for PANTAGES CAPITAL ACQUISITION Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Proqr therapeutics n.v. bullish and bearish analyst opinions

This section ties “Proqr therapeutics n.v. bullish and bearish analyst opinions” to ProQR Therapeutics N.V. (ticker PRQR), SEC Central Index Key 1612940, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Netherlands, formerly known as ProQR Therapeutics B.V.. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-09-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-03-12 by ProQR Therapeutics N.V. (CIK 1612940) — source document:

Our financial and other material information is routinely posted to and accessible on the Investors & Media section of our website, available at www.ProQR.com. Investors are encouraged to review the Investors & Media section of our website because we may post material information on that site that is not otherwise disseminated by us. Unless the context specifically indicates otherwise, references in this Annual Report to “ProQR Therapeutics N.V.”, “ProQR Therapeutics”, “ProQR”, “we”, “our”, “ours”, “us”, the “Company” and similar designations refer to ProQR Therapeutics N.V., a company organized under the laws of the Netherlands, and where appropriate, its consolidated subsidiaries. IFRS Based Information The audited financial statements as at December 31, 2025 and 2024, and for the years ended December 31, 2025, December 31, 2024 and December 31, 2023, included in the Annual Report have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

Financial trend for ProQR Therapeutics N.V. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -64,204,000 EUR (2022-12-31) to -42,184,000 EUR (2025-12-31), a change of +34.3%; total assets went from 171,321,000 EUR (2022-12-31) to 112,756,000 EUR (2025-12-31), a change of -34.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1612940, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures ProQR Therapeutics N.V. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ProQR Therapeutics N.V. (CIK 1612940) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 184 8-K or 6-K reports in ProQR Therapeutics N.V.’s recent EDGAR index, the 4 listed here run from 2026-08-13 to 2026-09-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1612940 is on the EDGAR company page; the latest 20-F there is dated 2026-03-12 and the oldest filing in the recent index dates from 2014-07-11. Insider trades for ProQR Therapeutics N.V. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pyrophyte acquisition corp. ii bullish and bearish analyst opinions

This section ties “Pyrophyte acquisition corp. ii bullish and bearish analyst opinions” to Pyrophyte Acquisition Corp. II (ticker PAII, PAII-UN, PAII-WT), SEC Central Index Key 2069238, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 425 dated 2026-10-15. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-30 by Pyrophyte Acquisition Corp. II (CIK 2069238) — source document:

References in this Form 10-K to “we,” “us,” “our” or the “Company” refer to Pyrophyte Acquisition Corp. II. References to our “management” or our “management team” refer to our officers and directors. Introduction We are a blank check company incorporated on May 1, 2025 as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). We have 24 months from the closing of our initial public offering (“IPO” or “Initial Public Offering”), or until such earlier liquidation date as our board of directors may approve (the “Completion Window”) to complete our initial Business Combination.

Financial trend for Pyrophyte Acquisition Corp. II from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $1.44 million (2025-09-30) to $1.50 million (2026-06-30), a change of +4.3%; total assets went from $203.48 million (2025-09-30) to $208.04 million (2026-06-30), a change of +2.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2069238, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Pyrophyte Acquisition Corp. II did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Pyrophyte Acquisition Corp. II (CIK 2069238) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Pyrophyte Acquisition Corp. II — registration statements, prospectuses and merger proxies — are filed on EDGAR; 4 such filings (424B4, 425, S-1, S-1/A) appear in its recent index, the newest dated 2026-10-15.

Current reports. Of the 5 8-K or 6-K reports in Pyrophyte Acquisition Corp. II’s recent EDGAR index, the 4 listed here run from 2025-07-24 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2069238 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2025-05-29. Insider trades for Pyrophyte Acquisition Corp. II appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Suncoke energy sxc latest news october 2026

This section ties “Suncoke energy sxc latest news october 2026” to SunCoke Energy, Inc. (ticker SXC), SEC Central Index Key 1514705, an EDGAR registrant classified as “Steel Works, Blast Furnaces & Rolling Mills (Coke Ovens)” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 3 dated 2026-10-06. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-20 by SunCoke Energy, Inc. (CIK 1514705) — source document:

SunCoke Energy, Inc. (“SunCoke Energy,” “SunCoke,” “Company,” “we,” “our” and “us”) is the largest independent producer of high-quality coke in the Americas, as measured by tons of coke produced each year, and has more than 65 years of coke production experience. Coke is produced by heating metallurgical coal in a refractory oven, which releases certain volatile components from the coal, thus transforming the coal into coke. Our coke is primarily used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron, and the majority of our sales are derived from blast furnace coke sales made under long-term, take-or-pay agreements.

Financial trend for SunCoke Energy, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $100.70 million (2022-12-31) to -$44.20 million (2025-12-31), a change of -143.9%; total assets went from $1.65 billion (2022-12-31) to $1.79 billion (2025-12-31), a change of +8.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1514705, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures SunCoke Energy, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: SunCoke Energy, Inc. (CIK 1514705) filed 147 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-01, and its overall latest filing is a 3 dated 2026-10-06. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 147 8-K or 6-K reports in SunCoke Energy, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-19 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1514705 is on the EDGAR company page; the latest 10-K there is dated 2026-02-20 and the oldest filing in the recent index dates from 2013-07-25. Insider trades for SunCoke Energy, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Viemed healthcare, inc. bullish and bearish analyst opinions

This section ties “Viemed healthcare, inc. bullish and bearish analyst opinions” to VIEMED HEALTHCARE, INC. (ticker VMD), SEC Central Index Key 1729149, an EDGAR registrant classified as “Services-Misc Health & Allied Services, NEC” and organised in British Columbia, Canada. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13D/A dated 2026-09-24. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-04 by VIEMED HEALTHCARE, INC. (CIK 1729149) — source document:

Viemed Healthcare, Inc. (the "Company" or "Viemed"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. The Company’s primary service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Viemed’s primary objective is to drive growth by increasing the number of patients served and the level of care provided through its technology-enabled, home-based clinical care and chronic disease management model. Viemed's care programs are designed specifically to treat patients in the home for less total cost and with a superior quality of care.

Financial trend for VIEMED HEALTHCARE, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $138.83 million (2022-12-31) to $270.28 million (2025-12-31), a change of +94.7%; net income (loss) went from $6.22 million (2022-12-31) to $14.93 million (2025-12-31), a change of +140.0%; total assets went from $117.04 million (2022-12-31) to $199.15 million (2025-12-31), a change of +70.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1729149, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures VIEMED HEALTHCARE, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on VIEMED HEALTHCARE, INC. (CIK 1729149) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-03, and the most recent 10-K annual report was filed 2026-03-04. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 91 8-K or 6-K reports in VIEMED HEALTHCARE, INC.’s recent EDGAR index, the 4 listed here run from 2026-06-02 to 2026-08-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1729149 is on the EDGAR company page; the latest 10-K there is dated 2026-03-04 and the oldest filing in the recent index dates from 2018-02-01. Insider trades for VIEMED HEALTHCARE, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Wimi hologram cloud inc. bullish and bearish analyst opinions

This section ties “Wimi hologram cloud inc. bullish and bearish analyst opinions” to WiMi Hologram Cloud Inc. (ticker WIMI), SEC Central Index Key 1770088, an EDGAR registrant classified as “Services-Prepackaged Software” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-09-17. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-24 by WiMi Hologram Cloud Inc. (CIK 1770088) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 74 A. Operating Results 74 B. Liquidity and Capital Resources 80 C. Research and Development, Patents and Licenses, etc. 84 D. Trend information 84 E. Critical Accounting Estimates 84 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 85 A. Directors, Senior Management and Employees 85 B. Compensation 86 C. Board Practices 87 D. Employees 92 E. Share Ownership 92 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 94 A. Major Shareholders 94 B. Related Party Transactions 94 C. Interests of Experts and Counsel 95 ITEM 8. FINANCIAL INFORMATION 95 A. Consolidated Statements and Other Financial Information 95 B. Significant Changes 96 ITEM 9. THE OFFER AND LISTING 96 A. Offer and listing details 96 B. Plan of Distribution 96 C. Markets 96 D. Selling Shareholders 96 E. Dilution 96 F. Expenses of the Issue 96 i Page ITEM 10.

Financial trend for WiMi Hologram Cloud Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 682,292,979 CNY (2022-12-31) to 422,245,411 CNY (2025-12-31), a change of -38.1%; net income (loss) went from -357,731,093 CNY (2022-12-31) to 309,246,488 CNY (2025-12-31), a change of +186.4%; total assets went from 1,260,341,366 CNY (2022-12-31) to 3,608,217,652 CNY (2025-12-31), a change of +186.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1770088, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures WiMi Hologram Cloud Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on WiMi Hologram Cloud Inc. (CIK 1770088) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 54 8-K or 6-K reports in WiMi Hologram Cloud Inc.’s recent EDGAR index, the 4 listed here run from 2025-10-24 to 2026-09-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1770088 is on the EDGAR company page; the latest 20-F there is dated 2026-04-24 and the oldest filing in the recent index dates from 2019-03-15. Insider trades for WiMi Hologram Cloud Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ascentage pharma group international bullish and bearish analyst opinions

This section ties “Ascentage pharma group international bullish and bearish analyst opinions” to ASCENTAGE PHARMA GROUP INTERNATIONAL (ticker AAPG), SEC Central Index Key 2023311, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-29 by ASCENTAGE PHARMA GROUP INTERNATIONAL (CIK 2023311) — source document:

Ascentage Pharma Group Corp Limited, a company incorporated in Hong Kong with limited liability, or Ascentage Pharma (HK), was established in May 2009. Dr. Yang, Dr. Zhai, Dr. Wang and Dr. Guo, our co-founders, were the initial majority shareholders of Ascentage Pharma (HK). In June 2010, Jiangsu Ascentage Pharma Co., Ltd, a limited liability company incorporated under the laws of the PRC, or Ascentage Jiangsu, was established as a wholly-owned subsidiary of Ascentage Pharma (HK). Ascentage Pharma (HK) went through a series of internal restructurings and equity financings in 2015 and 2016, pursuant to which Ascentage International Limited, a limited liability company incorporated in Hong Kong, or Ascentage International, Hongkong Sansheng Medical Limited, a company incorporated in Hong Kong with limited liability, and Shengda Taizhou Investment Centre LLP, or Shengda Taizhou, acquired equity interests in Ascentage Jiangsu from Ascentage Pharma (HK).

Financial trend for ASCENTAGE PHARMA GROUP INTERNATIONAL from annual reports, periods 2022-12-31 to 2024-12-31: revenue went from 209,711,000 CNY (2022-12-31) to 980,650,000 CNY (2024-12-31), a change of +367.6%; net income (loss) went from -882,924,000 CNY (2022-12-31) to -405,680,000 CNY (2024-12-31), a change of +54.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2023311, tags ProfitLoss, Revenue; 3 periods shown, dashes mark figures ASCENTAGE PHARMA GROUP INTERNATIONAL did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ASCENTAGE PHARMA GROUP INTERNATIONAL (CIK 2023311) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-29. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 76 8-K or 6-K reports in ASCENTAGE PHARMA GROUP INTERNATIONAL’s recent EDGAR index, the 4 listed here run from 2026-09-29 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2023311 is on the EDGAR company page; the latest 20-F there is dated 2026-04-29 and the oldest filing in the recent index dates from 2024-06-14. Insider trades for ASCENTAGE PHARMA GROUP INTERNATIONAL appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Biodexa pharmaceuticals plc bullish and bearish analyst opinions

This section ties “Biodexa pharmaceuticals plc bullish and bearish analyst opinions” to Biodexa Pharmaceuticals Plc (ticker BDRX), SEC Central Index Key 1643918, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in United Kingdom, formerly known as Midatech Pharma Plc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-14. Nothing here is a recommendation to trade the security.

Financial trend for Biodexa Pharmaceuticals Plc from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 699,000 GBP (2022-12-31) to 381,000 GBP (2023-12-31), a change of -45.5%; net income (loss) went from -7,656,000 GBP (2022-12-31) to -6,384,000 GBP (2025-12-31), a change of +16.6%; total assets went from 5,525,000 GBP (2022-12-31) to 18,179,000 GBP (2025-12-31), a change of +229.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1643918, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Biodexa Pharmaceuticals Plc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Biodexa Pharmaceuticals Plc (CIK 1643918) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 267 8-K or 6-K reports in Biodexa Pharmaceuticals Plc’s recent EDGAR index, the 4 listed here run from 2026-09-11 to 2026-10-14, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 731 recent EDGAR filings, Biodexa Pharmaceuticals Plc most often filed 6-K (267), 424B3 (243), EFFECT (35), CORRESP (21). A selection from 2026-10-14 to 2026-10-14:

The full record for CIK 1643918 is on the EDGAR company page; the latest 20-F there is dated 2026-03-27 and the oldest filing in the recent index dates from 2015-06-04. Insider trades for Biodexa Pharmaceuticals Plc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Estrella immunopharma, inc. bullish and bearish analyst opinions

This section ties “Estrella immunopharma, inc. bullish and bearish analyst opinions” to Estrella Immunopharma, Inc. (ticker ESLA, ESLAW), SEC Central Index Key 1844417, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in an unstated jurisdiction, formerly known as TradeUP Acquisition Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-08. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-18 by Estrella Immunopharma, Inc. (CIK 1844417) — source document:

We are a clinical-stage biopharmaceutical company developing T-cell therapies to address treatment challenges for patients with cancers and autoimmune diseases. Our strategy is to harness the evolutionary power of the human immune system to provide patients with potentially safer, more efficacious T-cell therapies compared to traditional CAR-T therapies. Leveraging cutting-edge cellular engineering technologies, we aim to overcome the limitations of current CAR-T therapies, such as high toxicity and prohibitive costs, so that T-cell therapy treatments can be accessible to a larger patient population. Lead Program Status Our innovative ARTEMIS ® T Cell Receptor Platform uniquely designs T cells that, unlike a traditional CAR-T cell, are activated and regulated upon engagement with cancer targets using cellular mechanisms more resembling those from the endogenous T-cell receptor (TCR).

Financial trend for Estrella Immunopharma, Inc. from annual reports, periods 2023-06-30 to 2025-12-31: net income (loss) went from -$11.11 million (2023-06-30) to -$13.06 million (2025-12-31), a change of -17.5%; total assets went from $3.03 million (2023-06-30) to $3.18 million (2025-12-31), a change of +4.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1844417, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Estrella Immunopharma, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Estrella Immunopharma, Inc. (CIK 1844417) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-18. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 61 8-K or 6-K reports in Estrella Immunopharma, Inc.’s recent EDGAR index, the 4 listed here run from 2026-01-13 to 2026-09-08, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1844417 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2021-02-19. Insider trades for Estrella Immunopharma, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Kewaunee scientific corporation bullish and bearish analyst opinions

This section ties “Kewaunee scientific corporation bullish and bearish analyst opinions” to KEWAUNEE SCIENTIFIC CORP /DE/ (ticker KEQU), SEC Central Index Key 55529, an EDGAR registrant classified as “Laboratory Apparatus & Furniture” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-09-11. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-06-26 by KEWAUNEE SCIENTIFIC CORP /DE/ (CIK 55529) — source document:

Kewaunee Scientific Corporation (the "Company") was founded in 1906, incorporated in Michigan in 1941, became publicly-held in 1968, and was reincorporated in Delaware in 1970. Our principal business is the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Our products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. Our acquisition of Nu Aire, Inc., ("Nu Aire"), completed in November 2024, complements the Company's portfolio through Nu Aire's biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products. Nu Aire is renowned for its manufacturing of biological safety cabinets, airflow products, CO2 incubators, ultralow freezers, animal handling equipment, pharmacy compounding isolators, and related parts and accessories.

Financial trend for KEWAUNEE SCIENTIFIC CORP /DE/ from annual reports, periods 2023-04-30 to 2026-04-30: net income (loss) went from $738,000 (2023-04-30) to $9.62 million (2026-04-30), a change of +1203.3%; total assets went from $118.90 million (2023-04-30) to $178.31 million (2026-04-30), a change of +50.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 55529, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures KEWAUNEE SCIENTIFIC CORP /DE/ did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on KEWAUNEE SCIENTIFIC CORP /DE/ (CIK 55529) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-09, and the most recent 10-K annual report was filed 2026-06-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 199 8-K or 6-K reports in KEWAUNEE SCIENTIFIC CORP /DE/’s recent EDGAR index, the 4 listed here run from 2026-08-25 to 2026-09-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 55529 is on the EDGAR company page; the latest 10-K there is dated 2026-06-26 and the oldest filing in the recent index dates from 2004-09-14. Insider trades for KEWAUNEE SCIENTIFIC CORP /DE/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Kochav defense acquisition corp. bullish and bearish analyst opinions

This section ties “Kochav defense acquisition corp. bullish and bearish analyst opinions” to Kochav Defense Acquisition Corp. (ticker KCHV, KCHVR, KCHVU), SEC Central Index Key 2053799, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a DEF 14A dated 2026-10-19. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-30 by Kochav Defense Acquisition Corp. (CIK 2053799) — source document:

We are a blank check company incorporated on January 7, 2025 as a Cayman Islands exempted company and formed for the purpose of effecting a Business Combination with one or more businesses or entities. We may pursue an initial Business Combination in any business or industry. To date, our efforts have been limited to (i) organizational activities, (ii) activities related to our Initial Public Offering, and (iii) searching for and consummating a Business Combination). As of the date of this Report, we have not selected any specific Business Combination target. We have generated no operating revenues to date, and we do not expect that we will generate operating revenues until we consummate our initial Business Combination.

Financial trend for Kochav Defense Acquisition Corp. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: net income (loss) went from $2.42 million (2025-09-30) to $2.13 million (2026-06-30), a change of -12.1%; total assets went from $257.56 million (2025-09-30) to $263.97 million (2026-06-30), a change of +2.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2053799, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Kochav Defense Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Kochav Defense Acquisition Corp. (CIK 2053799) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Kochav Defense Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 5 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2025-05-28.

Current reports. Of the 3 8-K or 6-K reports in Kochav Defense Acquisition Corp.’s recent EDGAR index, the 3 listed here run from 2025-05-29 to 2025-07-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2053799 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2025-02-26. Insider trades for Kochav Defense Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Melco international development limited bullish and bearish analyst opinions

This section ties “Melco international development limited bullish and bearish analyst opinions” to Melco International Development LTD (ticker none listed), SEC Central Index Key 1389153, an EDGAR registrant classified as “no SIC description” and organised in Hong Kong. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13D/A dated 2026-10-09. Nothing here is a recommendation to trade the security.

Analyst ratings, price targets and “bullish” or “bearish” calls on Melco International Development LTD (CIK 1389153) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

What kind of filer this is matters for “Melco international development limited bullish and bearish analyst opinions”: Melco International Development LTD’s EDGAR record from 2007-02-14 to 2026-10-09 consists only of 3 filings; 4 filings; CORRESP filings; SC 13D/A filings; SC 13G/A filings; SC TO-T filings; SC TO-T/A filings; SCHEDULE 13D/A filings; Schedule 13D ownership reports as an active large holder in another company; Schedule 13G ownership reports, filed when it held more than 5% of another company’s shares. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it; as a company organised in Hong Kong, its own reports would be with HKEX and its HKEXnews filings site (www.hkexnews.hk).

Other filings. Across its 40 recent EDGAR filings, Melco International Development LTD most often filed SC 13D/A (13), SC 13G (11), SCHEDULE 13D/A (3), SC TO-T/A (3). A selection from 2023-02-14 to 2026-10-09:

The full record for CIK 1389153 is on the EDGAR company page and the oldest filing in the recent index dates from 2007-02-14. Insider trades for Melco International Development LTD appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Neumora therapeutics, inc. common stock bullish and bearish analyst opinions

This section ties “Neumora therapeutics, inc. common stock bullish and bearish analyst opinions” to Neumora Therapeutics, Inc. (ticker NMRA), SEC Central Index Key 1885522, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-08-21. Nothing here is a recommendation to trade the security.

Financial trend for Neumora Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$130.90 million (2022-12-31) to -$236.93 million (2025-12-31), a change of -81.0%; total assets went from $426.23 million (2022-12-31) to $191.05 million (2025-12-31), a change of -55.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1885522, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Neumora Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Neumora Therapeutics, Inc. (CIK 1885522) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 31 8-K or 6-K reports in Neumora Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-29 to 2026-08-14, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 257 recent EDGAR filings, Neumora Therapeutics, Inc. most often filed 4 (101), 8-K (31), 144 (26), 3 (17). A selection from 2026-08-21 to 2026-08-21:

The full record for CIK 1885522 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2021-11-08. Insider trades for Neumora Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pt trans power marine tbk bullish and bearish analyst opinions

“PT … Tbk” is the Indonesian form for a public limited company (Perseroan Terbatas Terbuka), the label used by companies listed on IDX. The name “Pt trans power marine tbk” therefore points to a company organised in Indonesia, and its official disclosures are on the Indonesia Stock Exchange (IDX) company-announcement system, supervised by OJK (www.idx.co.id), not on EDGAR.

No SEC filer could be matched to “Pt trans power marine tbk bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Pt trans power marine tbk” appears in 2 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “trans” (search terms considered: trans, power, marine).

A broader EDGAR full-text search for the shorter phrase “Pt trans power” finds 2 filing documents; among the top 2, the filers mentioning it most are ADVISORS' INNER CIRCLE FUND (CIK 0000878719) (2). Those are documents that name the term, not proof that any of these filers is the business in the search.

The wording suggests a business based in Indonesia. Companies there file with Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “trans” is therefore the Indonesia regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 2 most relevant full-text hits returned for “Pt trans power marine tbk”, filings range from 2024-08-13 to 2025-08-25. The filers whose documents mention it most often are ADVISORS' INNER CIRCLE FUND (CIK 0000878719) (2 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 141 entities whose registered name contains the word “trans”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “trans” 141, “power” 472, “marine” 344. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “trans” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

What sec filings (10-k, 10-q, 8-k, s-1) has csquare made in 2026?

This section ties “What sec filings (10-k, 10-q, 8-k, s-1) has csquare made in 2026?” to Csquare, Inc. (ticker CSQR), SEC Central Index Key 2105398, an EDGAR registrant classified as “Services-Computer Programming, Data Processing, Etc.” and organised in DE, formerly known as BIF III US Aggregator (Delaware) LLC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-10. Nothing here is a recommendation to trade the security.

Financial trend for Csquare, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $244.75 million (2025-06-30) to $280.35 million (2026-06-30), a change of +14.5%; net income (loss) went from -$13.93 million (2025-06-30) to -$48.83 million (2026-06-30), a change of -250.6%; total assets was tagged only for 2026-06-30 at $6.00 billion. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2105398, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Csquare, Inc. did not tag for that period.

Csquare, Inc. has 37 filings in its recent EDGAR index, including 0 annual reports and 1 quarterly reports; its newest filing is a 10-Q from 2026-08-10.

Current reports. Of the 3 8-K or 6-K reports in Csquare, Inc.’s recent EDGAR index, the 3 listed here run from 2026-07-17 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 37 recent EDGAR filings, Csquare, Inc. most often filed 3 (15), 4 (7), 8-K (3), S-1/A (2). A selection from 2026-07-17 to 2026-08-10:

The full record for CIK 2105398 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-03-30. Insider trades for Csquare, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cisco qm cve

This section ties “Cisco qm cve” to CISCO SYSTEMS, INC. (ticker CSCO), SEC Central Index Key 858877, an EDGAR registrant classified as “Computer Communications Equipment” and organised in DE, formerly known as CISCO SYSTEMS, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 13F-HR dated 2026-10-15. Nothing here is a recommendation to trade the security.

Vulnerability records for Cisco QM. Security flaws are catalogued by the U.S. National Vulnerability Database (NVD), run by NIST, not by the SEC. A keyword query of the NVD on Oct 25, 2026 returned 0 CVE entries whose descriptions mention Cisco QM; 0 of them were published in 2026. Severity scores below are the CVSS base scores NVD lists; vendor advisories give fixed versions.

Business description, quoted from the 10-K filed 2026-09-02 by CISCO SYSTEMS, INC. (CIK 858877) — source document:

Cisco designs and sells a broad range of technologies including hardware, software, and artificial intelligence (AI) powered digital infrastructure to power, help secure, and draw insights from the Internet. We are incorporating AI into our product portfolios across networking, security, collaboration and observability, as well as integrating our products more tightly together into a platform. We are simplifying how our technology is delivered, managed and optimized and helping customers maximize the business value of their technology investments. We conduct our business globally and manage our business by geography. Our business is organized into the following three geographic segments: Americas; Europe, Middle East, and Africa (EMEA); and Asia Pacific, Japan, and China (APJC).

Financial trend for CISCO SYSTEMS, INC. from annual reports, periods 2023-07-29 to 2026-07-25: net income (loss) went from $12.61 billion (2023-07-29) to $13.27 billion (2026-07-25), a change of +5.2%; total assets went from $101.85 billion (2023-07-29) to $129.64 billion (2026-07-25), a change of +27.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 858877, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures CISCO SYSTEMS, INC. did not tag for that period.

Current reports. Of the 76 8-K or 6-K reports in CISCO SYSTEMS, INC.’s recent EDGAR index, the 4 listed here run from 2026-05-01 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 858877 is on the EDGAR company page; the latest 10-K there is dated 2026-09-02 and the oldest filing in the recent index dates from 2020-06-19. Insider trades for CISCO SYSTEMS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Invivyd therapeutics

This section ties “Invivyd therapeutics” to Invivyd, Inc. (ticker IVVD), SEC Central Index Key 1832038, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE, formerly known as Adagio Therapeutics, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-29, and this view starts from filings dated on or before 2026-08-17. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-05 by Invivyd, Inc. (CIK 1832038) (passage 2, continuing from the earlier excerpt) — source document:

By leveraging our capabilities, which we have developed through our experience with adintrevimab and pemivibart and over five years in the COVID-19 space, we aim to develop mAbs that could be used in prevention or treatment of serious viral infectious diseases, starting with COVID-19 and expanding into other high-need indications, such as respiratory syncytial virus (“RSV”) and measles. On March 22, 2024, we received emergency use authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for PEMGARDA injection, for intravenous (“IV”) use, a half-life extended investigational mAb, for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination.

Financial trend for Invivyd, Inc. from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $13.13 million (2025-09-30) to $14.29 million (2026-06-30), a change of +8.8%; net income (loss) went from -$10.47 million (2025-09-30) to -$44.39 million (2026-06-30), a change of -324.0%; total assets went from $139.16 million (2025-09-30) to $218.88 million (2026-06-30), a change of +57.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1832038, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Invivyd, Inc. did not tag for that period.

Invivyd, Inc. has 448 filings in its recent EDGAR index, including 5 annual reports and 16 quarterly reports; its newest filing is a 8-K from 2026-09-29.

Current reports. Of the 100 8-K or 6-K reports in Invivyd, Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-09 to 2026-07-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1832038 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2020-11-12. One example from this record is the 8-K filed 2026-09-01 (document). Insider trades for Invivyd, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Protagonist therapeutics sec filing october 2026 8-k

This section ties “Protagonist therapeutics sec filing october 2026 8-k” to Protagonist Therapeutics, Inc (ticker PTGX), SEC Central Index Key 1377121, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as Protagonist Therapeutics Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-02. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-25 by Protagonist Therapeutics, Inc (CIK 1377121) — source document:

Protagonist Therapeutics, Inc. (referred to as “Protagonist,” the “Company,” “we,” “our” or “us”) is an integrated discovery and development company with a validated technology platform. Our programs fall into three broad therapeutic areas: (i) inflammation and immunology (“I&I”), (ii) hematology and (iii) metabolic diseases. Our aim is to develop medicines for biologically and commercially validated targets which demonstrate a strong differentiation compared to existing therapies. Our Development Products and Discovery Programs Icotyde™ (icotrokinra) Icotyde™ (icotrokinra) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”), which underpins the inflammatory response in psoriasis and offers potential in other IL-23-mediated diseases. Icotyde is licensed to Janssen Biotech, Inc., a Johnson & Johnson company (“JNJ”), under a license and collaboration agreement initially entered into in 2017.

Financial trend for Protagonist Therapeutics, Inc from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $26.58 million (2022-12-31) to $46.02 million (2025-12-31), a change of +73.1%; net income (loss) went from -$127.39 million (2022-12-31) to -$130.15 million (2025-12-31), a change of -2.2%; total assets went from $247.93 million (2022-12-31) to $668.19 million (2025-12-31), a change of +169.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1377121, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 4 periods shown, dashes mark figures Protagonist Therapeutics, Inc did not tag for that period.

Protagonist Therapeutics, Inc has 704 filings in its recent EDGAR index, including 10 annual reports and 31 quarterly reports; its newest filing is a 4 from 2026-10-02.

Current reports. Of the 105 8-K or 6-K reports in Protagonist Therapeutics, Inc’s recent EDGAR index, the 4 listed here run from 2026-02-25 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1377121 is on the EDGAR company page; the latest 10-K there is dated 2026-02-25 and the oldest filing in the recent index dates from 2006-09-28. Insider trades for Protagonist Therapeutics, Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cantor equity partners v a (cepv) news october 2026

This section ties “Cantor equity partners v a (cepv) news october 2026” to Cantor Equity Partners V, Inc. (ticker CEPV), SEC Central Index Key 2034266, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 3 dated 2026-10-15. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by Cantor Equity Partners V, Inc. (CIK 2034266) — source document:

We are a blank check company incorporated on April 30, 2021 as a Cayman Islands exempted company for the purpose of effecting the Business Combination. Although we are not limited in our search for target businesses to a particular industry or sector for the purpose of consummating the Business Combination, we are focusing our search on companies operating in the financial services, digital assets, healthcare, real estate services, technology and software industries. Our executive officers consists of: ● Brandon G. Lutnick, our Chairman and Chief Executive Officer, who joined Cantor in April 2022 and has served as the Chairman and Chief Executive Officer of Cantor since February 2025; and ● Jane Novak, our Chief Financial Officer, who joined Cantor in October 2017 and, since then, has served as the Global Head of Accounting Policy.

Financial trend for Cantor Equity Partners V, Inc. from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) went from -$7,046 (2024-12-31) to $1.23 million (2025-12-31), a change of +17559.2%; total assets went from $306 (2024-12-31) to $252.00 million (2025-12-31), a change of +82351536.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2034266, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Cantor Equity Partners V, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Cantor Equity Partners V, Inc. (CIK 2034266) filed 4 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-15, and its overall latest filing is a 3 dated 2026-10-15. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 4 8-K or 6-K reports in Cantor Equity Partners V, Inc.’s recent EDGAR index, the 4 listed here run from 2025-11-05 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2034266 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2025-08-15. Insider trades for Cantor Equity Partners V, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Efscp october 2026 earnings expectations

This section ties “Efscp october 2026 earnings expectations” to ENTERPRISE FINANCIAL SERVICES CORP (ticker EFSC, EFSCP), SEC Central Index Key 1025835, an EDGAR registrant classified as “State Commercial Banks” and organised in DE, formerly known as ENTERBANK HOLDINGS INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-21. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-27 by ENTERPRISE FINANCIAL SERVICES CORP (CIK 1025835) — source document:

They are neither statements of historical fact nor guarantees or assurances of future performance. The Company cautions that the preceding list is not exhaustive of all possible risk factors and other factors could also adversely affect the Company’s results. You should understand that it is not possible to predict or identify all risk factors. Readers should carefully review all disclosures we file from time to time with the SEC which are available on the Company’s website at www.enterprisebank.com under “Investor Relations.” 1 General Development and Description of Our Business Enterprise Financial Services Corp, headquartered in Clayton, Missouri, is a financial holding company incorporated under Delaware law in December 1994. EFSC is the holding company for Enterprise Bank & Trust, a full-service financial institution offering banking and wealth management services to individuals and corporate clients primarily located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States.

Financial trend for ENTERPRISE FINANCIAL SERVICES CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $515.08 million (2022-12-31) to $888.41 million (2025-12-31), a change of +72.5%; net income (loss) went from $203.04 million (2022-12-31) to $201.37 million (2025-12-31), a change of -0.8%; total assets went from $13.05 billion (2022-12-31) to $17.30 billion (2025-12-31), a change of +32.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1025835, tags Assets, InterestAndDividendIncomeOperating, NetIncomeLoss; 4 periods shown, dashes mark figures ENTERPRISE FINANCIAL SERVICES CORP did not tag for that period.

For reported results, ENTERPRISE FINANCIAL SERVICES CORP’s (CIK 1025835) latest 10-Q is dated 2026-07-31 and its latest annual report (10-K) 2026-02-27. Earnings releases appear as 8-K Item 2.02 filings; 44 are in the recent index, the newest on 2026-10-21.

Current reports. Of the 141 8-K or 6-K reports in ENTERPRISE FINANCIAL SERVICES CORP’s recent EDGAR index, the 4 listed here run from 2026-07-22 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1025835 is on the EDGAR company page; the latest 10-K there is dated 2026-02-27 and the oldest filing in the recent index dates from 2017-01-24. Insider trades for ENTERPRISE FINANCIAL SERVICES CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Harrow hrow stock news latest

This section ties “Harrow hrow stock news latest” to HARROW, INC. (ticker HROW), SEC Central Index Key 1360214, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as HARROW HEALTH, INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-05, and this view starts from filings dated on or before 2026-05-11. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-02 by HARROW, INC. (CIK 1360214) (passage 3, continuing from the earlier excerpt) — source document:

We expect to commercially launch BYOOVIZ in mid-2026. ● OPUVIZ ® (aflibercept-yszy) 0.05mL injection, an FDA-approved EYLEA biosimilar indicated for the treatment of patients with Wet AMD, Macular Edema following RVO, Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). We expect to commercially launch OPUVIZ in mid-2027. ● BYQLOVI TM (clobetasol propionate ophthalmic suspension) 0.05% a high-potency ophthalmic corticosteroid formulated using proprietary APNT® nanoparticle formulation technology, indicated for the treatment of post-operative inflammation and pain following ocular surgery. We expect to commercially launch BYQLOVI in mid-2026. ● VIGAMOX ® (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. 4 ● ILEVRO ® (nepafenac ophthalmic suspension) 0.3%, a non-steroidal, anti-inflammatory eye drop indicated for pain and inflammation associated with cataract surgery. ● FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1%, a corticosteroid prepared as a sterile topical ophthalmic suspension indicated for use in the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Financial trend for HARROW, INC. from annual reports, periods 2018-12-31 to 2021-12-31: revenue went from $41.37 million (2018-12-31) to $72.48 million (2021-12-31), a change of +75.2%; net income (loss) went from $14.62 million (2018-12-31) to -$18.01 million (2021-12-31), a change of -223.1%; total assets went from $49.45 million (2018-12-31) to $98.33 million (2021-12-31), a change of +98.8%. Values are as filed and not adjusted for restatements, splits or currency.

Current reports. Of the 268 8-K or 6-K reports in HARROW, INC.’s recent EDGAR index, the 4 listed here run from 2026-03-02 to 2026-03-24, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1360214 is on the EDGAR company page; the latest 10-K there is dated 2026-03-02 and the oldest filing in the recent index dates from 2006-07-21. One example from this record is the SCHEDULE 13G/A filed 2026-07-31 (document). Insider trades for HARROW, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pluri plx-pad news october 2026

Also searched as: pluri plx-pad october 2026 news

This section ties “Pluri plx-pad news october 2026” to Pluri Inc. (ticker PLUR), SEC Central Index Key 1158780, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in NV, formerly known as PLURISTEM THERAPEUTICS INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-20. Nothing here is a recommendation to trade the security.

Financial trend for Pluri Inc. from annual reports, periods 2023-06-30 to 2026-06-30: revenue went from $287,000 (2023-06-30) to $1.02 million (2026-06-30), a change of +254.0%; net income (loss) went from -$28.32 million (2023-06-30) to -$23.82 million (2026-06-30), a change of +15.9%; total assets went from $50.80 million (2023-06-30) to $24.88 million (2026-06-30), a change of -51.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1158780, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Pluri Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Pluri Inc. (CIK 1158780) filed 248 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-20, and its overall latest filing is a 8-K dated 2026-10-20. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 248 8-K or 6-K reports in Pluri Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-14 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 950 recent EDGAR filings, Pluri Inc. most often filed 4 (305), 8-K (248), 10-Q (54), 3 (35). A selection from 2026-09-11 to 2026-10-15:

The full record for CIK 1158780 is on the EDGAR company page; the latest 10-K there is dated 2026-09-10 and the oldest filing in the recent index dates from 2001-09-10. Insider trades for Pluri Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET